Request a sample of IsoFast Hot Start Bst Colour Mix
 

« Previous article
Ready-to-use Custom ...

27th June 2023  Content supplied by: CosmosID

CosmosID Announces Metabolomics Services, Expands Multi-Omics Capabilities


CosmosID, a leader in the field of high-resolution microbiome analysis, has launched its metabolomics services that will provide enhanced support for multi-omics microbiome research. CosmosID, based in Germantown, MD, and Stockholm, Sweden, produces CLIA-certified, GCP-compliant laboratory services, including standardized and validated metagenomics/molecular assays, industry-leading custom bioinformatics, and the CosmosID-HUB software platform

Metagenomics, metatranscriptomics, and metabolomics provides greater insight into the role of the microbiome in a given environment by identifying both microbial composition and their expressed genes, but also the metabolites being produced by the microbiome. Thus, key drivers of microbiome function and composition are identified accurately, providing definitive and actionable data to power microbiome research.

The CosmosID metabolomics service comprises a combination of Liquid Chromatography–Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectroscopy (GC-MS), deployed to test samples and includes CosmosID metabolomics profiling in an "untargeted" approach. This enables broad coverage and highly accurate detection of +100,000 metabolites. Combining retention time, mass, and MS fragmentation of metabolites allows individual profiling during elution through their respective MS test and results are compiled into a comprehensive report.

The test report is a listing of all detected metabolites within each sample as well as relative quantitation. Additionally, CosmosID runs a sample-type specific targeted panel to complement the "untargeted" analysis in each test, to provide greater in-depth analysis of each sample (including absolute quantitation). If more extensive data is needed, CosmosID also offers customizable panels of over 650 target metabolites tailored to client specific needs.

"Capturing full details of the microbiome will drive translational research, a core goal at CosmosID," said Manoj Dadlani, CEO of CosmosID. "Knowing the metabolite profile of each sample is important to understand the microbiome as a system. By combining the CosmosID industry leading strain-level microbiome resolution and functional analysis with metabolite profiling, insight into the microbiome's functionality and role will be enhanced. We believe this approach yields more actionable microbiome research and helps us link observations from microbiome studies with biological mechanisms."

"There is no question that understanding the interplay amongst all components of the microbiome is essential to advance our knowledge of microbial systems," said Dr. Rita Colwell, Founder and Chairman of CosmosID. "However, we need to understand functional relationships between and among strains comprising the microbiome. Being able to understand their function brings us closer to knowing what drives a microbiome in its natural environment."

Visit www.cosmosid.com


Share on:

Tags:


Date Published: 27th June 2023

Source article link: View


View full company details